In contrast, in the face of BCMA loss induced by CRISPR/Cas9 or in a recurrent plasmacytoma after cilta-cel treatment in a patient, anti-BCMA-anti-TACI CARs retained activity; this leads us to conclude that this configuration is the superior dual-specific construct. The gene discussed is TNFRSF17; the disease is plasmacytoma.